Crohn's Disease

Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease
Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease
Endpoints
Takeda
Finch Therapeutics
microbiome
Crohn's Disease
Flag link:
Provention Bio's J&J-licensed Crohn's drug stumbles in mid-stage study
Provention Bio's J&J-licensed Crohn's drug stumbles in mid-stage study
Endpoints
Provention Bio
JNJ
Crohn's Disease
clinical trials
PRV-6527
Flag link:
$60M B round to propel Landos through Phase II IBD trials
$60M B round to propel Landos through Phase II IBD trials
BioCentury
Landos Biopharma
clinical trials
ulcerative colitis
Crohn's Disease
BT-11
Flag link:
Lilly’s Mirikizumab succeeds in phase 2 study in Crohn’s disease
Lilly’s Mirikizumab succeeds in phase 2 study in Crohn’s disease
Pharmaceutical Business Review
Eli Lilly
Crohn's Disease
mirikizumab
Flag link:
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Enpoints
Takeda
Shire
inflammatory bowel disease
IBD
ulcerative colitis
Crohn's Disease
M&A
SHP647
Flag link:
Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+
Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+
CP Wire
Enterome
Takeda
Crohn's Disease
EB8018
Flag link:
Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+
Enterome
Takeda
Crohn's Disease
EB8018
Flag link:
Stelara Shines in Three Year Crohn's Disease Study
Stelara Shines in Three Year Crohn's Disease Study
CP Wire
Janssen
JNJ
Stelara
Crohn's Disease
clinical trials
Flag link:
Stelara Shines in Three Year Crohn's Disease Study
Jannsen
JNJ
Stelara
Crohn's Disease
Flag link:
Arena 3 for 3 as Crohn’s drug meets proof-of-concept test
Arena 3 for 3 as Crohn’s drug meets proof-of-concept test
Fierce Biotech
Arena Pharmaceuticals
olorinab
Crohn's Disease
Flag link:
RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3
RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3
Fierce Biotech
Redhill Biopharma
clinical trials
Crohn's Disease
RHB-104
Flag link:
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Fierce Pharma
JNJ
Tremfya
MorphoSys
Janssen
Crohn's Disease
clinical trials
Flag link:
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
Yahoo/Zacks.com
AbbVie
Upadacitinib
Crohn's Disease
Flag link:
J&J strikes potential $1B JAK inhibitor deal with Theravance
J&J strikes potential $1B JAK inhibitor deal with Theravance
Biopharma Dive
JNJ
JAK inhibitors
Theravance
TD-1473
drug development
Crohn's Disease
ulcerative colitis
Flag link:
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Yahoo/Reuters
Pfizer
biosimilars
JNJ
Remicade
Ifixi
rheumatoid arthritis
Crohn's Disease
Flag link:
Price Hikes Insulate Celgene From a Failure
Price Hikes Insulate Celgene From a Failure
Motley Fool
Celgene
drug pricing
GED-301
Crohn's Disease
Flag link:
With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII
With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII
Endpoints
JNJ
Provention Bio
IBD
inflammatory bowel disease
PRV-6527
Crohn's Disease
PRV-300
ulcerative colitis
Flag link:
Johnson & Johnson shows off under-pressure Stelara's latest indication—Crohn's—in new DTC spot
Johnson & Johnson shows off under-pressure Stelara's latest indication—Crohn's—in new DTC spot
Fierce Pharma
JNJ
Stelara
Crohn's Disease
drug advertising
DTC ads
Flag link:
Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Fierce Biotech
JNJ
Protagonist Therapeutics
M&A
Crohn's Disease
PTG-200
Flag link:
AbbVie's JAK-1 inhibitor hits the mark in Crohn's disease
AbbVie's JAK-1 inhibitor hits the mark in Crohn's disease
BioPharma Dive
AbbVie
JAK inhibitors
Crohn's Disease
Upadacitinib
Flag link:

Pages